Congestive heart failure calcium channel blockers
|
Congestive heart failure Microchapters |
|
Differentiating Congestive heart failure from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Medical Therapy: |
|
Surgical Therapy: |
|
ACC/AHA Guideline Recommendations:
|
|
Specific Groups: |
|
Congestive heart failure calcium channel blockers On the Web |
|
Congestive heart failure calcium channel blockers in the news |
|
Blogs on Congestive heart failure calcium channel blockers</small> |
|
Directions to Hospitals Treating Congestive heart failure calcium channel blockers |
|
Risk calculators and risk factors for Congestive heart failure calcium channel blockers |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Lakshmi Gopalakrishnan, M.B.B.S. [2]
Overview
Although calcium channel blockers cause vasodilation and may reduce afterload in the setting of heart failure, their overall benefit in heart failure is minimized by the fact that they have a negative inotropic effect and by the reflex activation of the sympathetic nervous system. These agents are therefore not recommended as vasodilators in patients with systolic dysfunction,however they may be useful as antihypertensive agents in patients with diastolic dysfunction.
2009 ACC/AHA Focused Update and 2005 Guidelines for the Diagnosis and Management of Chronic Heart Failure in the Adult (DO NOT EDIT) [1][2]
Calcium channel blockers in Patients Presenting With Heart Failure (DO NOT EDIT) [1][2]
| Class I |
| "1. Drugs known to adversely affect the clinical status of patients with current or prior symptoms of heart failure and reduced left ventricular ejection fraction (LVEF) should be avoided or withdrawn whenever possible (e.g., nonsteroidal anti-inflammatory drugs, most antiarrhythmic drugs, and most calcium channel blocking drugs.[3][4][5][6][7][8][9] (Level of Evidence: B) " |
| Class III (No Benefit) |
| "1. Calcium channel blocking drugs are not indicated as routine treatment for heart failure in patients with current or prior symptoms of heart failure and reduced left ventricular ejection fraction (LVEF). [10][11][12][13] (Level of Evidence: A) " |
Vote on and Suggest Revisions to the Current Guidelines
External Links
- The ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult [1]
- 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation [2]
References
- ↑ 1.0 1.1 1.2 Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW, Antman EM, Smith SC Jr, Adams CD, Anderson JL, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B; American College of Cardiology; American Heart Association Task Force on Practice Guidelines; American College of Chest Physicians; International Society for Heart and Lung Transplantation; Heart Rhythm Society. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation. 2005 Sep 20; 112(12): e154-235. Epub 2005 Sep 13. PMID 16160202
- ↑ 2.0 2.1 2.2 Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, Ganiats TG et al. (2009) 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 119 (14):1977-2016. DOI:10.1161/CIRCULATIONAHA.109.192064 PMID: 19324967
- ↑ Heerdink ER, Leufkens HG, Herings RM, Ottervanger JP, Stricker BH, Bakker A (May 1998). "NSAIDs associated with increased risk of congestive heart failure in elderly patients taking diuretics". Archives of Internal Medicine 158 (10): 1108–12. PMID 9605782. Retrieved on 2012-04-05.
- ↑ Herchuelz A, Derenne F, Deger F, Juvent M, Van Ganse E, Staroukine M, Verniory A, Boeynaems JM, Douchamps J (March 1989). "Interaction between nonsteroidal anti-inflammatory drugs and loop diuretics: modulation by sodium balance". The Journal of Pharmacology and Experimental Therapeutics 248 (3): 1175–81. PMID 2703968. Retrieved on 2012-04-05.
- ↑ Gottlieb SS, Robinson S, Krichten CM, Fisher ML (October 1992). "Renal response to indomethacin in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy". The American Journal of Cardiology 70 (9): 890–3. PMID 1529943. Retrieved on 2012-04-05.
- ↑ Bank AJ, Kubo SH, Rector TS, Heifetz SM, Williams RE (September 1991). "Local forearm vasodilation with intra-arterial administration of enalaprilat in humans". Clinical Pharmacology and Therapeutics 50 (3): 314–21. PMID 1655327. Retrieved on 2012-04-05.
- ↑ (August 1989) "Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators". The New England Journal of Medicine 321 (6): 406–12. doi:10.1056/NEJM198908103210629. PMID 2473403. Retrieved on 2012-04-05.
- ↑ (July 1992) "Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. The Cardiac Arrhythmia Suppression Trial II Investigators". The New England Journal of Medicine 327 (4): 227–33. doi:10.1056/NEJM199207233270403. PMID 1377359. Retrieved on 2012-04-05.
- ↑ Pratt CM, Eaton T, Francis M, Woolbert S, Mahmarian J, Roberts R, Young JB (September 1989). "The inverse relationship between baseline left ventricular ejection fraction and outcome of antiarrhythmic therapy: a dangerous imbalance in the risk-benefit ratio". American Heart Journal 118 (3): 433–40. PMID 2476016. Retrieved on 2012-04-05.
- ↑ (August 1988) "The effect of diltiazem on mortality and reinfarction after myocardial infarction. The Multicenter Diltiazem Postinfarction Trial Research Group". The New England Journal of Medicine 319 (7): 385–92. doi:10.1056/NEJM198808183190701. PMID 2899840. Retrieved on 2012-04-06.
- ↑ Reed SD, Friedman JY, Velazquez EJ, Gnanasakthy A, Califf RM, Schulman KA (July 2004). "Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT)". American Heart Journal 148 (1): 122–8. doi:10.1016/j.ahj.2003.12.040. PMID 15215801. Retrieved on 2012-04-06.
- ↑ Setaro JF, Zaret BL, Schulman DS, Black HR, Soufer R (October 1990). "Usefulness of verapamil for congestive heart failure associated with abnormal left ventricular diastolic filling and normal left ventricular systolic performance". The American Journal of Cardiology 66 (12): 981–6. PMID 2220622. Retrieved on 2012-04-06.
- ↑ Packer M, O'Connor CM, Ghali JK, Pressler ML, Carson PE, Belkin RN, Miller AB, Neuberg GW, Frid D, Wertheimer JH, Cropp AB, DeMets DL (October 1996). "Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group". The New England Journal of Medicine 335 (15): 1107–14. doi:10.1056/NEJM199610103351504. PMID 8813041. Retrieved on 2012-04-06.
Navigation WikiDoc | WikiPatient | Popular pages | Recently Edited Pages | Recently Added
Pictures
There is no pharmaceutical or device industry support for this site and we need your viewer supported Donations | Editorial Board | Governance | Licensing | Disclaimers | Avoid Plagiarism | Policies
Table of Contents In Alphabetical Order | By Individual Diseases | Signs and Symptoms | Physical Examination | Lab Tests | Drugs
Editor Tools Become an Editor | Editors Help Menu | Create a Page | Edit a Page | Upload a Picture or File | Printable version | Permanent link | Maintain Pages | What Pages Link HereThere is no pharmaceutical or device industry support for this site and we need your viewer supported Donations | Editorial Board | Governance | Licensing | Disclaimers | Avoid Plagiarism | Policies
